CHINA NUOKANG SPADR (NKBP) – Analyst Ratings
-
Oppenheimer Maintains an 'Outperform' on China Nuokang Bio-Pharmaceutical (NKBP); 3Q11 Review: Lukewarm Quarter But Bumpy Path Ahead
-
Jefferies & Co Initiates Coverage on China Nuokang Bio-Pharmaceutical (NKBP) with a Buy
-
Back to NKBP Stock Lookup